C-(3-氯-联苯-4-基)-甲胺盐酸盐 | 893649-04-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: C-(3-氯-联苯-4-基)-甲胺盐酸盐
• 英文名称: (3'-chlorobiphenyl-4-yl)methylamine
• 英文别名: (3'-chloro-[1,1'-biphenyl]-4-yl)methanamine；[4-(3-Chlorophenyl)phenyl]methanamine
• CAS: 893649-04-2
• 化学式: C₁₃H₁₂ClN
• 分子量: 217.698
• InChiKey: ZQIQUBLIBQYSLO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2921499090

反应信息

• 作为反应物：
  描述：

  C-(3-氯-联苯-4-基)-甲胺盐酸盐 在 盐酸 作用下， 以 水 、 乙酸乙酯 为溶剂， 反应 1.0h， 以4.37 g的产率得到[4-(3-氯苯基)苯基]甲胺盐酸盐
  参考文献：
  名称：

  (Biphenyl-4-yl)methylammonium Chlorides: Potent Anticonvulsants That Modulate Na⁺ Currents

  摘要：

  We have reported that compounds containing a biaryl linked unit (Ar-X-Ar') modulated Na+ currents by promoting slow inactivation and fast inactivation processes and by inducing frequency (use)-dependent inhibition of Na+ currents. These electrophysiological properties have been drugs. In this study, we demonstrate that the readily accessible associated with the mode of action of several antiepileptic (biphenyl-4-yl)methylammonium chlorides (compound class B) exhibited a broad range of anticonvulsant activities in animal models, and in the maximal electroshock seizure test the activity of (3'-trifluoromethoxybiphenyl-4-yl)methylammonium chloride (8) exceeded that of phenobarbital and phenytoin upon oral administration to rats. Electrophysiological studies of 8 using mouse catecholamine A-differentiated cells and rat embryonic cortical neurons confirmed that 8 promoted slow and fast inactivation in both cell types but did not affect the frequency (use)-dependent block of Na+ currents.

  DOI：

  10.1021/jm4007092
• 作为产物：
  描述：

  对溴苄胺 在 potassium carbonate 、 sodium hydroxide 作用下， 以 水 、 乙腈 为溶剂， 反应 1.25h， 生成 C-(3-氯-联苯-4-基)-甲胺盐酸盐
  参考文献：
  名称：

  Substituted N-(Biphenyl-4′-yl)methyl (R)-2-Acetamido-3-methoxypropionamides: Potent Anticonvulsants That Affect Frequency (Use) Dependence and Slow Inactivation of Sodium Channels

  摘要：

  We prepared 13 derivatives of N-(biphenyl-4'-yl)methyl (R)-2-acetamido-3-methoxypropionamide that differed in type and placement of a R-substituent in the terminal aryl unit. We demonstrated that the R-substituent impacted the compound's whole animal and cellular pharmacological activities. In rodents, select compounds exhibited excellent anticonvulsant activities and protective indices (PI = TD50/ED50) that compared favorably with clinical antiseizure drugs. Compounds with a polar, aprotic R-substituent potently promoted Na+ channel slow inactivation and displayed frequency (use) inhibition of Na+ currents at low micromolar concentrations. The possible advantage of affecting these two pathways to decrease neurological hyperexcitability is discussed.

  DOI：

  10.1021/jm500707r

文献信息

• Synthesis and Structure–Activity Relationship Studies of <i>N</i>-Benzyl-2-phenylpyrimidin-4-amine Derivatives as Potent USP1/UAF1 Deubiquitinase Inhibitors with Anticancer Activity against Nonsmall Cell Lung Cancer
  作者：Thomas S. Dexheimer、Andrew S. Rosenthal、Diane K. Luci、Qin Liang、Mark A. Villamil、Junjun Chen、Hongmao Sun、Edward H. Kerns、Anton Simeonov、Ajit Jadhav、Zhihao Zhuang、David J. Maloney

  DOI：10.1021/jm5010495

  日期：2014.10.9

  screen of >400000 compounds and subsequent medicinal chemistry optimization of small molecules that inhibit the deubiquitinating activity of USP1/UAF1. Ultimately, these efforts led to the identification of ML323 (70) and related N-benzyl-2-phenylpyrimidin-4-amine derivatives, which possess nanomolar USP1/UAF1 inhibitory potency. Moreover, we demonstrate a strong correlation between compound IC50 values

  泛素缀合或解缀合的失调与包括癌症在内的许多人类疾病的发病机制有关。去泛素化酶 USP1（泛素特异性蛋白酶 1）与 UAF1（USP1 相关因子 1）结合，是已知的 DNA 损伤反应调节剂，并已被证明是有希望的抗癌靶点。为了进一步评估 USP1/UAF1 作为治疗靶点，我们对超过 400000 种化合物进行了定量高通量筛选，并随后对抑制 USP1/UAF1 去泛素化活性的小分子进行了药物化学优化。最终，这些努力导致鉴定出 ML323 ( 70 ) 和相关的N-benzyl-2-phenylpyrimidin-4-amine 衍生物，具有纳摩尔 USP1/UAF1 抑制效力。此外，我们证明了USP1/UAF1 抑制的化合物 IC 50值与非小细胞肺癌细胞的活性之间存在很强的相关性，特别是单泛素化 PCNA (Ub-PCNA) 水平增加和细胞存活率降低。我们的结果确定了 USP1/UAF1 去泛
• New Piperazine Compound and Use Thereof as a HCV Polymerase Inhibitor
  申请人：Abe Hiroyuki

  公开号：US20080081818A1

  公开（公告）日：2008-04-03

  The present invention relates to a compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, or a solvate thereof and an anti-HCV agent and an HCV polymerase inhibitor containing this compound. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.

  本发明涉及一种由以下式[I]表示的化合物，其中每个符号如规范中定义，或其药学上可接受的盐，或其溶剂化合物，以及含有该化合物的抗HCV剂和HCV聚合酶抑制剂。本发明的化合物基于HCV聚合酶抑制活性显示出抗HCV活性，并且可用作预防或治疗丙型肝炎的药剂。
• NEW PIPERAZINE COMPOUND AND USE THEREOF AS A HCV POLYMERASE INHIBITOR
  申请人：Abe Hiroyuki

  公开号：US20120107273A1

  公开（公告）日：2012-05-03

  The present invention relates to a compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, or a solvate thereof and an anti-HCV agent and an HCV polymerase inhibitor containing this compound. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.

  本发明涉及一种由下式[I]表示的化合物，其中每个符号如规范所定义，或其药学上可接受的盐，或其溶剂化物，以及含有该化合物的抗HCV剂和HCV聚合酶抑制剂。本发明的化合物基于HCV聚合酶抑制活性表现出抗HCV活性，可作为预防或治疗丙型肝炎的药剂。
• NOVEL PIPERAZINE COMPOUND, AND USE THEREOF AS HCV POLYMERASE INHIBITOR
  申请人：Japan Tobacco, Inc.

  公开号：EP2009004A1

  公开（公告）日：2008-12-31

  The present invention relates to a compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, or a solvate thereof and an anti-HCV agent and an HCV polymerase inhibitor containing this compound. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.

  本发明涉及下式[I]所代表的化合物 其中各符号如说明书中所定义，或其药学上可接受的盐，或其溶液，以及含有该化合物的抗HCV药剂和HCV聚合酶抑制剂。本发明的化合物具有基于 HCV 聚合酶抑制活性的抗 HCV 活性，可用作丙型肝炎的预防或治疗剂。
• Structure-Based Design of Novel G-Protein-Coupled Receptor TAAR1 Agonists as Potential Antipsychotic Drug Candidates
  作者：Zhenzhen Zhou、Weifeng Zhang、Fabao Zhao、Yanying Sun、Na Wang、Jie Cheng、Peng Zhan、Fan Yang、Jin-Peng Sun、Xinyong Liu、Dongwei Kang

  DOI：10.1021/acs.jmedchem.4c00195

  日期：2024.3.14

  seriously undesirable effects. Trace amine-associated receptor 1 (TAAR1) has emerged as an ideal target for the design of antischizophrenia drugs, with the ability to mediate multiple psychological functions by sensing endogenous amine-containing metabolites without the side effects of catalepsy. In this work, a series of novel TAAR1 agonists were designed based on the structural analysis of the TAAR1 activation

  现有的抗精神病药物未能治疗精神分裂症的认知障碍，并引发了许多严重的不良反应。痕量胺相关受体 1 (TAAR1) 已成为抗精神分裂症药物设计的理想靶标，能够通过感知内源性含胺代谢物来介导多种心理功能，而不会产生僵住症的副作用。在这项工作中，基于TAAR1激活口袋的结构分析，设计了一系列新型TAAR1激动剂。其中， 6e表现出有效的TAAR1-G s /G q双通路激活特性，与仅激活TAAR1-G s通路的临床候选药物SEP-363856不同。在啮齿动物模型中， 6e显着减轻 MK-801 诱导的精神分裂症样认知表型，但不会诱发僵直症。此外， 6e·HCl表现出良好的药代动力学（ T 1/2 = 2.31 h， F = 39%）和安全特性。这些都表明6e·HCl可作为治疗精神分裂症的新候选药物。